Prognostic Risk

Approximately 1 out of 4 patients has poor prognostic risk

  • 20% to 26% of patients with advanced RCC are poor risk at the time of the 1st-line treatment decision*
*Percentage of poor-risk patients based on published analyses using the Database Consortium, International Kidney Cancer Working Group, Cleveland Clinic Foundation, and Memorial Sloan-Kettering Cancer Center risk models.1-5

Prognostic risk is a predictor of patient survival

  • The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer list prognostic risk stratification as an important consideration for patients with advanced RCC6
  • Evidence shows that prognostic risk is one of a number of factors to consider when managing advanced RCC1,7

 

 
 
REFERENCES
  1. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289-296.
  2. Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141-148.
  3. Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-5799.
  4. Manola J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. Clin Cancer Res. 2011;17(16):5443-5450.
  5. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110(3):543-550.
  6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer V.3.2015. © National Comprehensive Cancer Network, Inc 2014. All rights reserved. Accessed January 13, 2015. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
  7. Mekhail TM, Abou-Jawde RM. BouMerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832-841.